Evidence map›Paper›PMID 39195317›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience.

Shelley Kuang, Kaitlin Chen, Sachin Sayal, Gajeni Prabahan, Mary R Rabey, Lisa W Le, Andrew Seto, Frances A Shepherd, Geoffrey Liu, Penelope Bradbury and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shelley KuangDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.ORCID 0000-0002-3478-4750
Kaitlin ChenDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Sachin SayalDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Gajeni PrabahanDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Mary R RabeyDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Lisa W LeDepartment of Biostatistics, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0002-0084-9915
Andrew SetoDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.
Frances A ShepherdDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Geoffrey LiuDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Penelope BradburyDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Adrian G SacherDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Jennifer H LawDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
Peter SabatiniDepartment of Biostatistics, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0002-3361-0468
Tracy L StockleyDepartment of Biostatistics, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0002-4476-9722
Ming S TsaoDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.ORCID 0000-0002-9160-5405
Natasha B LeighlDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.

Funding

Princess Margaret Cancer Foundation 886712001168
6 · The paper itself

Abstract

In advanced non-squamous non-small-cell lung cancer (NSCLC), routine testing with next-generation sequencing (NGS) is recommended to identify actionable genomic alterations (AGAs). The therapeutic implications of repeated NGS testing on synchronous and metachronous tumors are unclear. Between February 2017 and October 2020, NSCLC samples from a single institution were reflex-tested using a targeted 15-gene NGS panel (TruSight Tumor 15, Illumina). Thirty-eight patients were identified with multiple NGS results from 82 samples: 11% were from single unifocal, 51% were from synchronous, and 38% were from metachronous tumors. Changes in

Indexed as

Carcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasms, Multiple Primarymetachronousmultifocal lung cancernext generation sequencingnon-small-cell lung cancersynchronous

Identifiers

PMID39195317
PMCPMC11352737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.